

DACLIZUMAB

TRADE NAME	ZINBRYTA
DRUG CLASS	Monoclonal antibody (humanised) for multiple sclerosis
AVAILABILITY	Prefilled pen or syringe contains 150 mg/mL of daclizumab. Also contains sodium succinate, succinic acid, sodium chloride and polysorbate-80. Contains 0.14 mmol of sodium per dose. ¹ The solution is clear to opalescent and colourless to slightly yellow. ¹
pH	No information
PREPARATION	Allow 30 minutes for the pen or syringe to reach room temperature before use. ¹
STABILITY	Store at 2 to 8 °C. Do not freeze. Stable for 30 days below 30 °C. Protect from light. ¹
ADMINISTRATION	
IM injection	Not recommended ¹
SUBCUT injection	Inject into the thigh, abdomen or upper arm. ¹ Suitable for self-administration in selected patients. ¹
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	Not applicable
INCOMPATIBILITY	No information
SPECIAL NOTES	If a dose is missed by less than 2 weeks, it can be given as soon as possible and the patient can remain on their original monthly schedule. If it is more than 2 weeks, they should skip the missed dose. ¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 11/10/2017.